Carlos A Molina Selected Research

Tissue Plasminogen Activator (Alteplase)

2/2024	Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
3/2023	Association of Time of Day With Outcomes Among Patients Triaged for a Suspected Severe Stroke in Nonurban Catalonia.
10/2022	Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial.
1/2021	Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis.
11/2020	Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
1/2019	Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA.
1/2019	Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
1/2018	Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients With Proximal Intracranial Occlusions.
5/2017	Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III.
5/2017	Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlos A Molina Research Topics

Disease

136	Stroke (Strokes) 05/2024 - 06/2002
71	Ischemic Stroke 05/2024 - 04/2003
21	Hemorrhage 01/2024 - 02/2003
20	Transient Ischemic Attack 10/2022 - 10/2003
17	Infarction (Infarctions) 01/2021 - 06/2002
13	Cerebral Hemorrhage 05/2024 - 07/2003
10	Embolic Stroke 01/2022 - 02/2004
9	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021 - 09/2004
9	Myocardial Infarction 10/2019 - 06/2008
8	Atrial Fibrillation 05/2024 - 08/2008
8	Brain Ischemia (Cerebral Ischemia) 10/2019 - 02/2003
6	Pathologic Constriction (Stenosis) 12/2020 - 01/2005
5	Thrombosis (Thrombus) 01/2024 - 03/2007
5	Cerebral Infarction 01/2023 - 01/2013
4	Hematoma 05/2024 - 03/2009
4	Arterial Occlusive Diseases (Arterial Occlusive Disease) 04/2024 - 05/2010
4	Diabetes Mellitus 11/2019 - 05/2003
4	Hemorrhagic Stroke 09/2017 - 06/2006
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2015 - 07/2005
4	Ischemia 12/2011 - 02/2003
3	Hypertension (High Blood Pressure) 03/2024 - 01/2007
3	Atherosclerosis 12/2020 - 12/2007
3	Neoplasms (Cancer) 09/2013 - 11/2002
3	Brain Injuries (Brain Injury) 12/2010 - 07/2005
3	Inflammation (Inflammations) 12/2010 - 07/2007
3	Hyperglycemia 09/2007 - 05/2003
2	Neurologic Manifestations (Neurological Manifestations) 05/2024 - 11/2020
2	COVID-19 02/2024 - 11/2020
2	Brain Infarction 01/2024 - 09/2017
2	Intracranial Thrombosis (Cerebral Thrombosis) 01/2023 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2022 - 09/2013
2	Ganglion Cysts (Ganglion) 08/2019 - 01/2019
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 03/2012 - 01/2012
1	Rare Diseases (Rare Disease) 05/2024
1	Tobacco Use Disorder (Nicotine Dependence) 03/2024
1	Dyslipidemias (Dyslipidemia) 03/2024
1	Alcoholism (Alcohol Abuse) 03/2024
1	Factor XI Deficiency (Hemophilia C) 01/2024
1	Cardiomyopathies (Cardiomyopathy) 04/2022

Drug/Important Bio-Agent (IBA)

52	Tissue Plasminogen Activator (Alteplase)FDA Link 02/2024 - 06/2002
21	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2023 - 12/2015
18	TicagrelorIBA 01/2023 - 12/2015
8	Biomarkers (Surrogate Marker)IBA 04/2022 - 08/2008
7	Proteins (Proteins, Gene)FDA Link 04/2022 - 07/2003
7	Matrix Metalloproteinases (MMPs)IBA 03/2012 - 02/2003
6	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 05/2003
5	Cytidine Triphosphate (CTP)IBA 01/2023 - 01/2017
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2019 - 03/2007
4	Matrix Metalloproteinase 9 (Gelatinase B)IBA 06/2006 - 02/2003
3	Hemostatics (Antihemorrhagics)IBA 05/2024 - 09/2012
3	Factor XIa (Coagulation Factor XIa)IBA 01/2024 - 10/2022
3	EnzymesIBA 12/2022 - 04/2003
3	Thrombin FDA Link 01/2022 - 04/2003
3	AnticoagulantsIBA 01/2022 - 11/2017
3	C-Reactive ProteinIBA 05/2008 - 10/2003
2	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/2024 - 10/2022
2	milvexianIBA 01/2024 - 10/2022
2	Neuroprotective AgentsIBA 01/2023 - 01/2021
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 10/2022 - 12/2015
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 10/2021
2	RivaroxabanIBA 11/2019 - 01/2019
2	Vitamin K FDA Link 11/2019 - 11/2015
2	salicylhydroxamic acid (SHAM)IBA 08/2019 - 01/2019
2	boldenone undecylenate (Equipoise)IBA 01/2019 - 12/2010
2	UbiquitinIBA 02/2012 - 06/2008
2	Ligases (Synthetase)IBA 02/2012 - 12/2010
2	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2012 - 12/2011
2	danaparoid (Orgaran)FDA Link 12/2007 - 02/2004
2	Plasminogen Activator Inhibitor 1IBA 09/2004 - 06/2004
2	ImmunosorbentsIBA 07/2003 - 04/2003
1	PRT064445IBA 05/2024
1	eculizumab FDA Link 05/2024
1	Factor Xa InhibitorsIBA 05/2024
1	2,2,4,4-tetramethylpiperdine-1-oxylIBA 04/2024
1	Tenecteplase FDA Link 04/2024
1	CholesterolIBA 03/2024
1	Antihypertensive Agents (Antihypertensives)IBA 02/2024
1	Immunoglobulin FragmentsIBA 02/2024
1	Glycoproteins (Glycoprotein)IBA 02/2024
1	platelet membrane glycoprotein VIIBA 02/2024
1	glenzocimabIBA 02/2024
1	Toll-Like Receptor 4IBA 01/2023
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 12/2022
1	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 12/2022
1	Angiopoietin-2IBA 01/2022
1	Dabigatran FDA Link 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Troponin T (Troponin T1)IBA 01/2022

Therapy/Procedure

52	Therapeutics 05/2024 - 01/2003
28	Thrombectomy 02/2024 - 01/2014
10	Time-to-Treatment 09/2014 - 09/2004
7	Thrombolytic Therapy 01/2019 - 07/2005
6	Endovascular Procedures 01/2023 - 01/2013
4	Aftercare (After-Treatment) 05/2017 - 01/2007
3	Secondary Prevention 08/2023 - 08/2008
3	Stents 01/2021 - 11/2006
2	Contraindications 08/2019 - 01/2014
2	Punctures 03/2018 - 05/2013
2	Length of Stay 05/2017 - 05/2015
2	Microbubbles 10/2008 - 02/2006